Hyperlipidemia (Dyslipidemia)

A 52-year-old man with obesity, hypertension, and type 2 diabetes mellitus presents for routine evaluation. Laboratory investigations reveal total cholesterol of 290 mg/dL, LDL cholesterol of 195 mg/dL, triglycerides of 240 mg/dL, and HDL cholesterol of 34 mg/dL. Physical examination demonstrates tendon xanthomas over the Achilles tendon. Family history is significant for premature myocardial infarction in his father at age 45 years. Diagnosis?

Diagnosis is Severe Hypercholesterolemia with Familial Hypercholesterolemia (FH), most consistent with Heterozygous FH.

This patient has:

1.      LDL-C 195 mg/dL

2.      Achilles tendon xanthomas

3.      Premature coronary disease in a first-degree relative

4.      Additional ASCVD risk factors, including type 2 diabetes, hypertension, and obesity

He also has moderate hypertriglyceridemia with triglycerides of 240 mg/dL.

If the LDL-C of 195 mg/dL represents his untreated baseline, he meets criteria for definite clinical FH by the Dutch Lipid Clinic Network score.

1. Definition

Dyslipidemia refers to abnormal concentrations of circulating lipids or atherogenic lipoproteins, including:

1.      Elevated LDL cholesterol

2.      Elevated triglycerides

3.      Elevated non-HDL cholesterol

4.      Elevated apolipoprotein B

5.      Elevated lipoprotein(a)

6.      Low HDL cholesterol

Familial hypercholesterolemia is an inherited disorder characterized by lifelong elevation of LDL-C and markedly increased risk of premature atherosclerotic cardiovascular disease.

Severe hypercholesterolemia is defined by LDL-C ≥190 mg/dL.

2. Familial Hypercholesterolemia

FH is most commonly caused by pathogenic variants affecting LDL clearance, including:

1.      LDLR

2.      APOB

3.      PCSK9

Other rarer genetic causes and phenocopies exist.

The major consequences are:

1.      Lifelong exposure to elevated LDL-C

2.      Accelerated atherosclerosis

3.      Premature coronary artery disease

4.      Increased lifetime ASCVD risk

3. Clinical Features

Most dyslipidemia is asymptomatic until ASCVD develops.

Features suggesting FH include:

1.      Markedly elevated LDL-C

2.      Tendon xanthomas

3.      Premature coronary artery disease

4.      Strong family history of premature ASCVD

5.      Corneal arcus at a young age

Tendon xanthomas, particularly involving the Achilles or extensor tendons, are highly suggestive of FH.

Low HDL-C is associated with increased ASCVD risk, but raising HDL-C pharmacologically is not a treatment target.

4. Diagnosis of FH

FH can be diagnosed clinically using validated criteria such as the Dutch Lipid Clinic Network score.

The LDL-C component of this score should use the untreated LDL-C level.

4.1 Dutch Lipid Clinic Network Score in This Patient

If LDL-C 195 mg/dL is the untreated baseline:

1.      First-degree male relative with premature coronary disease before age 55:
1 point

2.      Tendon xanthomas:
6 points

3.      Untreated LDL-C 191 to 250 mg/dL:
3 points

Total score = 10 points

Interpretation:

1.      >8 points: definite FH

2.      6 to 8 points: probable FH

3.      3 to 5 points: possible FH

4.      0 to 2 points: unlikely FH

Therefore:

If LDL-C 195 mg/dL is the untreated baseline, DLCN score = 10, meeting criteria for definite clinical FH.

If the patient is already receiving lipid-lowering therapy, use the documented pretreatment LDL-C for formal DLCN scoring.

5. Laboratory Evaluation

5.1 Standard Lipid Profile

Assess:

1.      Total cholesterol

2.      LDL-C

3.      HDL-C

4.      Triglycerides

5.      Non-HDL-C

In this patient:

Non-HDL-C = 290 - 34 = 256 mg/dL

This confirms a very high burden of atherogenic lipoproteins.

Modern LDL-C estimation methods such as the Martin-Hopkins or Sampson equations are generally more accurate than the traditional Friedewald equation, particularly when triglycerides are elevated.

5.2 Non-HDL-C and Apolipoprotein B

Because this patient's triglycerides are 240 mg/dL, assessment of atherogenic burden should not rely on LDL-C alone.

In adults with triglycerides ≥150 mg/dL, measurement of non-HDL-C or ApoB is preferred over LDL-C alone to guide clinical decision-making.

ApoB reflects the total number of circulating atherogenic lipoprotein particles.

Measurement is particularly useful in:

1.      Hypertriglyceridemia

2.      Diabetes mellitus

3.      Metabolic dysfunction

4.      Discordance between LDL-C and non-HDL-C

5.      Assessment of residual ASCVD risk

LDL-C nevertheless remains a central treatment target in FH.

5.3 Lipoprotein(a)

Lp(a) should be measured at least once in all adults.

An Lp(a):

1.      ≥50 mg/dL

2.      ≥125 nmol/L

is considered an important ASCVD risk-enhancing level.

Because FH and premature family ASCVD are present, Lp(a) measurement is particularly relevant in this patient.

6. Evaluation for Secondary Causes

Before attributing severe hypercholesterolemia entirely to FH, evaluate for secondary contributors.

Important causes include:

1.      Hypothyroidism

2.      Nephrotic syndrome

3.      Chronic kidney disease

4.      Cholestatic liver disease

5.      Poorly controlled diabetes

6.      Obesity and dietary factors

7.      Selected medications

Evaluation may include:

1.      TSH

2.      HbA1c or glucose

3.      Serum creatinine and eGFR

4.      Urinalysis or urine albumin assessment

5.      Liver biochemical tests

6.      Medication and alcohol review

Secondary contributors do not exclude coexisting FH.

7. Genetic Testing and Family Screening

In adults with severe hypercholesterolemia and suspected FH, panel-based genetic testing can be useful and should be considered.

Important points:

1.      Genetic testing can confirm a pathogenic FH variant

2.      It may improve risk stratification

3.      It facilitates cascade screening

4.      A negative genetic test does not exclude clinically diagnosed FH

5.      Genetic confirmation is not required before starting treatment

Cascade screening:

1.      Screen first-degree relatives

2.      Extend cascade screening to additional relatives, including second-degree relatives when appropriate

3.      Use lipid testing and, when a familial pathogenic variant is identified, targeted genetic testing

4.      Children in affected families should be screened early

8. Pathophysiology

Atherosclerosis is driven primarily by retention of ApoB-containing lipoproteins within the arterial wall.

1.      LDL and other ApoB-containing particles enter and become retained in the arterial intima

2.      Inflammatory responses and macrophage uptake develop

3.      Foam cells and atherosclerotic plaques form

4.      Progressive plaque burden increases the risk of myocardial infarction, ischemic stroke, and peripheral arterial disease

In FH, lifelong LDL-C exposure substantially accelerates this process.

9. Management

9.1 Lifestyle

Lifestyle therapy is essential but is usually insufficient by itself in FH.

Recommend:

1.      Heart-healthy dietary pattern

2.      Reduce saturated fat

3.      Avoid trans fats

4.      Increase soluble fiber

5.      Weight reduction when appropriate

6.      Regular physical activity

7.      Tobacco cessation

8.      Optimize diabetes and blood pressure control

9.      Minimize alcohol, particularly with elevated triglycerides

9.2 Statin Therapy

For LDL-C ≥190 mg/dL, treatment should begin with maximally tolerated statin therapy regardless of calculated 10-year ASCVD risk.

High-intensity options include:

1.      Atorvastatin 40 to 80 mg daily

2.      Rosuvastatin 20 to 40 mg daily

A high-intensity statin generally aims for an LDL-C reduction of ≥50%.

Standard population risk calculators should not be used to decide whether to treat a patient with FH.

9.3 Lipid Goals in This Patient

This patient has:

1.      Severe hypercholesterolemia

2.      Definite clinical FH if LDL-C 195 mg/dL is untreated

3.      Type 2 diabetes

4.      Hypertension

5.      Obesity

He has no documented clinical ASCVD in the vignette.

Appropriate treatment goals are:

1.      LDL-C <70 mg/dL

2.      Non-HDL-C <100 mg/dL

3.      ApoB <70 mg/dL, when measured

4.      ≥50% reduction in LDL-C from untreated baseline

His current LDL-C of 195 mg/dL and non-HDL-C of 256 mg/dL are therefore markedly above goal.

9.4 Additional LDL-Lowering Therapy

If maximally tolerated statin therapy does not achieve the treatment goal, add nonstatin therapy.

Options include:

1.      Ezetimibe

2.      PCSK9 monoclonal antibody

o    Evolocumab

o    Alirocumab

3.      Bempedoic acid

Choice depends on:

1.      Degree of additional LDL-C lowering required

2.      ASCVD risk

3.      Statin tolerance

4.      Cost and access

5.      Patient preference

Because FH often requires large absolute LDL-C reductions, combination therapy is frequently necessary.

9.5 Inclisiran

Inclisiran is a small interfering RNA therapy that reduces hepatic PCSK9 production.

In adults with severe hypercholesterolemia and LDL-C ≥100 mg/dL despite maximally tolerated statin therapy with or without ezetimibe, inclisiran is a reasonable option for additional LDL-C lowering.

Cardiovascular outcomes trials remain pending. Therefore, PCSK9 monoclonal antibodies such as evolocumab or alirocumab are preferred when therapies with established cardiovascular outcome benefit are available and appropriate.

10. Hypertriglyceridemia

This patient's triglycerides are 240 mg/dL, representing moderate hypertriglyceridemia.

Management should focus on:

1.      Weight reduction

2.      Improved glycemic control

3.      Exercise

4.      Reduction of refined carbohydrates and added sugars

5.      Limiting alcohol

6.      Statin-based ASCVD risk reduction

7.      Evaluation for secondary causes

At TG 240 mg/dL, fibrate therapy is not routinely indicated solely to prevent pancreatitis.

Pancreatitis risk becomes clinically important with:

1.      TG ≥500 mg/dL

2.      Particularly TG ≥1000 mg/dL

For severe hypertriglyceridemia, fenofibrate or prescription omega-3 fatty acids may be considered to reduce triglycerides and pancreatitis risk.

10.1 Icosapent Ethyl

Because this patient is:

1.      Age ≥50 years

2.      Has type 2 diabetes

3.      Has additional ASCVD risk factors

4.      Has TG 150 to 499 mg/dL

Icosapent ethyl may be considered for additional ASCVD risk reduction if triglycerides remain elevated after lifestyle optimization and maximally tolerated statin therapy and LDL-C has been reduced to <100 mg/dL.

The immediate priority in this patient is aggressive LDL-C reduction.

11. Monitoring

1.      Repeat lipid profile after starting or changing lipid-lowering therapy

2.      Assess absolute and percentage LDL-C reduction

3.      Assess adherence and lifestyle measures

4.      Escalate treatment promptly if lipid goals are not achieved

5.      Follow non-HDL-C or ApoB when triglycerides remain elevated

6.      Obtain baseline ALT before initiating statin therapy

7.      Routine serial liver-enzyme monitoring is unnecessary; repeat testing if symptoms or clinical findings suggest hepatotoxicity

8.      Do not routinely measure CK; check CK when significant or severe muscle symptoms suggest myopathy

9.      Continue long-term surveillance for ASCVD

12. Key Clinical Insight

LDL-C ≥190 mg/dL + Achilles tendon xanthomas + premature coronary disease in a first-degree relative strongly suggests familial hypercholesterolemia.

In this patient:

If LDL-C 195 mg/dL is the untreated baseline, LDL-C 191 to 250 mg/dL contributes 3 points + tendon xanthomas 6 points + premature coronary disease in his father 1 point = DLCN score 10 = definite clinical FH.

Because he also has diabetes, hypertension, obesity, and moderate hypertriglyceridemia, intensive and usually combination lipid-lowering therapy is indicated.

Treatment goals include:

1.      LDL-C <70 mg/dL

2.      Non-HDL-C <100 mg/dL

3.      ApoB <70 mg/dL when measured

4.      ≥50% LDL-C reduction from untreated baseline

References

1.      Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423.

2.      Ahmad Z, Agarwala A, Cuchel M, et al. Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association. Journal of Clinical Lipidology. 2026;20(4):708-737. doi:10.1016/j.jacl.2026.01.011.

3.      Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190.

Chronic Liver Disease (CLD)

A 56-year-old man with a history of long-term alcohol use presents with progressive abdominal distension, lower-limb edema, fatigue, and confusion. Physical examination reveals jaundice, spider angiomas, ascites with shifting dullness, and asterixis. Laboratory investigations show elevated bilirubin, prolonged INR, low albumin, and thrombocytopenia. Ultrasound demonstrates a nodular liver with splenomegaly and ascites. Diagnosis?

Diagnosis is Decompensated Cirrhosis, most likely due to Alcohol-Associated Liver Disease.

This patient has portal hypertension, ascites, impaired hepatic function, and probable overt hepatic encephalopathy, indicating hepatic decompensation.

1. Definition

Cirrhosis is an advanced stage of chronic liver disease characterized by:

1.      Diffuse hepatic fibrosis

2.      Regenerative nodules

3.      Distortion of normal hepatic architecture

4.      Development of portal hypertension and hepatic dysfunction

Fibrosis may partially regress when the underlying cause is successfully treated, but clinically significant portal hypertension and its complications may persist.

2. Etiology

2.1 Common Causes

1.      Alcohol-associated liver disease

2.      Metabolic dysfunction-associated steatotic liver disease, including MASH

3.      Chronic hepatitis B

4.      Chronic hepatitis C

In this patient, long-term alcohol use makes alcohol-associated cirrhosis the most likely etiology, although coexisting causes should be excluded when appropriate.

2.2 Other Causes

1.      Autoimmune hepatitis

2.      Hereditary hemochromatosis

3.      Wilson disease

4.      Alpha-1 antitrypsin deficiency

5.      Primary biliary cholangitis

6.      Primary sclerosing cholangitis

7.      Budd-Chiari syndrome

3. Pathophysiology

1.      Chronic hepatic injury activates hepatic stellate cells

2.      Collagen and extracellular matrix deposition cause progressive fibrosis

3.      Fibrosis and regenerative nodules distort hepatic architecture

4.      Increased intrahepatic resistance produces portal hypertension

5.      Splanchnic vasodilation and neurohormonal activation cause sodium and water retention

6.      Progressive hepatocellular dysfunction impairs synthetic and metabolic function

7.      Portosystemic shunting and impaired ammonia handling contribute to hepatic encephalopathy

4. Compensated vs Decompensated Cirrhosis

4.1 Compensated Cirrhosis

1.      No previous major decompensating event

2.      May be asymptomatic

3.      Aminotransferases may be normal or mildly elevated

4.      Clinically significant portal hypertension may already be present

4.2 Decompensated Cirrhosis

Major first decompensating events include:

1.      Clinically evident ascites or hepatic hydrothorax

2.      Variceal bleeding

3.      Overt hepatic encephalopathy, West Haven grade II or higher

Jaundice may accompany advanced decompensation but is not, by itself, a universally accepted defining first decompensating event.

Important complications include:

1.      Spontaneous bacterial peritonitis

2.      Hepatorenal syndrome

3.      Recurrent variceal bleeding

4.      Progressive liver failure

A first major decompensating event should prompt hepatology assessment and consideration of liver transplantation.

5. Clinical Features

5.1 Portal Hypertension

1.      Ascites

2.      Splenomegaly

3.      Gastroesophageal varices

4.      Portal hypertensive gastropathy

5.      Thrombocytopenia

Thrombocytopenia commonly results from splenic sequestration and reduced hepatic thrombopoietin production.

5.2 Chronic Liver Disease Stigmata

1.      Jaundice

2.      Spider angiomas

3.      Palmar erythema

4.      Gynecomastia

5.      Testicular atrophy

6.      Muscle wasting and sarcopenia

5.3 Hepatic Encephalopathy

Hepatic encephalopathy is a clinical diagnosis.

Features include:

1.      Sleep-wake disturbance

2.      Cognitive or personality changes

3.      Confusion

4.      Asterixis

5.      Somnolence

6.      Coma in severe disease

This patient's confusion and asterixis strongly support probable overt hepatic encephalopathy, but other causes of altered mental status should be excluded, including:

1.      Infection

2.      Intracranial pathology

3.      Alcohol withdrawal

4.      Wernicke encephalopathy

5.      Medications or sedatives

6.      Hypoglycemia

7.      Electrolyte disturbances

6. Diagnosis

Diagnosis is based on the combination of:

1.      Clinical findings

2.      Laboratory abnormalities

3.      Imaging

4.      Noninvasive assessment when needed

6.1 Laboratory Findings

Common abnormalities include:

1.      Elevated bilirubin

2.      Low albumin

3.      Prolonged INR

4.      Thrombocytopenia

5.      Hyponatremia in advanced disease

6.      Renal dysfunction

AST and ALT may be normal or only mildly elevated in advanced cirrhosis.

Albumin and INR reflect aspects of hepatic synthetic function, but both are influenced by factors outside the liver.

INR in cirrhosis does not accurately predict bleeding risk.

6.2 Etiologic Evaluation

When appropriate, evaluate for:

1.      Hepatitis B and C

2.      Metabolic risk factors for MASLD

3.      Autoimmune hepatitis

4.      Hemochromatosis

5.      Wilson disease

6.      Alpha-1 antitrypsin deficiency

7.      Cholestatic liver disease

Laboratory patterns such as AST greater than ALT, macrocytosis, or elevated GGT may support alcohol-associated liver disease but are not diagnostic.

7. Imaging

7.1 Abdominal Ultrasound With Doppler

May demonstrate:

1.      Nodular liver

2.      Splenomegaly

3.      Ascites

4.      Portosystemic collaterals

5.      Portal or hepatic vein thrombosis

6.      Abnormal portal venous flow

In this patient, a nodular liver with splenomegaly and ascites strongly supports cirrhosis with portal hypertension.

7.2 Transient Elastography

Useful for noninvasive assessment of liver stiffness, particularly earlier in chronic liver disease.

7.3 Liver Biopsy

Usually not required when cirrhosis is clinically and radiologically established.

Biopsy may be considered when the diagnosis or etiology remains uncertain. A transjugular approach may be preferred when significant ascites or bleeding concerns are present.

8. Major Complications

8.1 Ascites

Diagnosis

Diagnostic paracentesis should be performed in:

1.      New-onset ascites

2.      Patients with cirrhosis and ascites admitted emergently to the hospital

3.      Patients with ascites who develop fever, abdominal pain, encephalopathy, hypotension, GI bleeding, or renal deterioration

Initial fluid studies include:

1.      Cell count and differential

2.      Ascitic albumin

3.      Total protein

4.      Ascitic fluid culture in emergently hospitalized patients, preferably by bedside inoculation into aerobic and anaerobic blood-culture bottles

For uncomplicated new outpatient ascites without concern for infection, routine culture is not always necessary.

SAAG ≥1.1 g/dL strongly supports portal hypertension.

Routine correction of elevated INR or thrombocytopenia before uncomplicated paracentesis is generally not required.

Treatment

1.      Sodium restriction, approximately 2 g/day

2.      Spironolactone with or without furosemide

3.      A common combination is spironolactone 100 mg plus furosemide 40 mg daily

4.      Large-volume paracentesis for tense or refractory ascites

5.      If >5 L is removed, give albumin approximately 6 to 8 g per liter removed

6.      Consider TIPS for appropriately selected patients with refractory ascites

Routine fluid restriction is unnecessary unless significant hyponatremia is present.

Avoid NSAIDs. ACE inhibitors and ARBs are generally avoided in patients with cirrhosis and ascites because of the risk of hypotension and renal dysfunction.

8.2 Spontaneous Bacterial Peritonitis

Diagnosis

Ascitic PMN ≥250 cells/µL warrants treatment for SBP.

Do not delay treatment while awaiting culture results.

Treatment

1.      Third-generation cephalosporin, such as cefotaxime or ceftriaxone, for many community-acquired cases

2.      Broader treatment when healthcare-associated infection or multidrug-resistant organisms are likely

3.      IV albumin using the standard regimen:

o    1.5 g/kg on day 1

o    1 g/kg on day 3

Albumin provides greatest benefit in patients with renal dysfunction or severe hepatic dysfunction.

Secondary antibiotic prophylaxis is generally indicated after an episode of SBP. Primary prophylaxis is reserved for selected high-risk patients.

8.3 Esophageal Varices and Acute Variceal Hemorrhage

Primary Prevention

In patients with cirrhosis and varices who require primary prophylaxis:

1.      Use a nonselective beta blocker, such as carvedilol, propranolol, or nadolol, when appropriate

2.      Carvedilol is preferred in suitable patients because of its greater portal-pressure reduction

3.      Endoscopic variceal ligation is an alternative when nonselective beta blockers are contraindicated or not tolerated

4.      In patients with ascites, reduce or discontinue the nonselective beta blocker if:

o    SBP remains <90 mm Hg

o    MAP remains <65 mm Hg

o    HRS-AKI develops

5.      The nonselective beta blocker may be restarted and retitrated after blood pressure recovers or HRS-AKI resolves

Acute Variceal Hemorrhage

1.      Stabilize airway and circulation

2.      Use a restrictive transfusion strategy, generally initiating red-cell transfusion around Hb 7 g/dL and targeting approximately 7 to 8 g/dL

3.      Individualize transfusion according to ongoing bleeding, cardiovascular disease, age, and hemodynamic status

4.      Start octreotide, terlipressin, or somatostatin immediately

5.      Start antibiotic prophylaxis, commonly ceftriaxone

6.      Perform upper endoscopy within approximately 12 hours after appropriate stabilization

7.      Perform endoscopic variceal ligation for bleeding esophageal varices

8.      Continue vasoactive therapy for approximately 2 to 5 days

Consider preemptive TIPS within 72 hours, ideally within 24 hours, in selected high-risk patients, including:

1.      Child-Pugh C with score 10 to 13

2.      Child-Pugh B with score >7 and active bleeding at endoscopy

Secondary Prevention

Following recovery from esophageal variceal bleeding:

1.      Carvedilol or another nonselective beta blocker plus repeated endoscopic variceal ligation

2.      Carvedilol is preferred when tolerated

3.      Consider TIPS when standard secondary prophylaxis fails or is not feasible

8.4 Hepatic Encephalopathy

Common precipitants include:

1.      Infection

2.      Gastrointestinal bleeding

3.      Constipation

4.      Dehydration or overdiuresis

5.      Hypokalemia

6.      Renal dysfunction

7.      Sedative medications

Treatment

1.      Identify and treat the precipitating factor

2.      Lactulose is first-line therapy

3.      Titrate lactulose to approximately 2 to 3 soft stools daily

4.      Add rifaximin to lactulose for prevention of recurrent overt hepatic encephalopathy, particularly after the second episode

Serum ammonia correlates poorly with clinical severity and should not be used alone to diagnose or grade hepatic encephalopathy.

A normal ammonia level in a patient suspected of having overt hepatic encephalopathy should prompt reconsideration of the diagnosis.

8.5 Hepatorenal Syndrome With Acute Kidney Injury

Current HRS-AKI criteria include:

1.      Cirrhosis with ascites

2.      Increase in creatinine ≥0.3 mg/dL within 48 hours or ≥50% from baseline within 7 days, and/or urine output ≤0.5 mL/kg/h for ≥6 hours

3.      No improvement within approximately 24 hours after adequate volume resuscitation when clinically indicated

4.      No strong evidence for another primary cause of AKI

A routine 48-hour albumin challenge is no longer required to diagnose HRS-AKI.

Treatment

1.      Treat precipitating factors

2.      Stop nephrotoxic or hemodynamically harmful medications when appropriate

3.      Terlipressin plus albumin is preferred where available and appropriate

4.      Norepinephrine is an effective alternative, generally in an ICU setting

5.      Monitor carefully for volume overload and respiratory complications

6.      Liver transplantation is the definitive treatment in suitable candidates

9. Hepatocellular Carcinoma

Surveillance

For patients with cirrhosis who remain candidates for HCC-directed treatment:

1.      Liver ultrasound plus AFP

2.      Every 6 months

AFP alone is insufficient.

Routine surveillance is generally not recommended in patients with Child-Pugh C cirrhosis who are not transplant candidates.

Diagnosis

Suspicious lesions are evaluated using:

1.      Multiphasic CT

2.      Contrast-enhanced MRI

Characteristic imaging in an appropriate at-risk patient may establish HCC without biopsy.

10. Severity Assessment

10.1 Child-Pugh Score

Includes:

1.      Bilirubin

2.      Albumin

3.      INR or PT

4.      Ascites

5.      Hepatic encephalopathy

Classification:

1.      Class A: 5 to 6

2.      Class B: 7 to 9

3.      Class C: 10 to 15

Child-Pugh class should not be equated directly with compensated versus decompensated cirrhosis.

10.2 MELD 3.0

For adults, MELD 3.0 incorporates:

1.      Bilirubin

2.      INR

3.      Creatinine

4.      Sodium

5.      Albumin

6.      Female sex

The equation also contains interaction terms.

MELD 3.0 is used for short-term mortality assessment and transplant prioritization in applicable systems.

Age is not itself a variable in the adult MELD 3.0 equation.

A fixed MELD threshold should not be the sole trigger for transplant referral.

11. General Management

1.      Treat the underlying cause

2.      Recommend complete alcohol abstinence

3.      Provide evidence-based treatment for alcohol use disorder

4.      Refer for hepatology and transplant assessment when appropriate

5.      Vaccinate against HAV and HBV if nonimmune, influenza, pneumococcus, COVID-19, and other age-appropriate infections

6.      Maintain protein intake of approximately 1.2 to 1.5 g/kg ideal body weight/day

7.      Do not routinely restrict protein, including in hepatic encephalopathy

8.      Minimize prolonged fasting and consider a late-evening snack

9.      Avoid NSAIDs and unnecessary sedatives

10.  Avoid nephrotoxins when possible

11.  Screen for malnutrition, frailty, and sarcopenia

Acetaminophen is generally preferred to NSAIDs when analgesia is required and is commonly limited to approximately 2 g/day, with additional caution in ongoing heavy alcohol use or malnutrition.

12. Liver Transplantation

Patients with decompensated cirrhosis should be considered for liver transplantation.

Consider transplant evaluation after:

1.      First or recurrent hepatic decompensation

2.      Clinically significant or refractory ascites

3.      Variceal hemorrhage

4.      Recurrent hepatic encephalopathy

5.      HRS-AKI

6.      Progressive jaundice or hepatic dysfunction

7.      Increasing MELD score

8.      HCC meeting transplant criteria

9.      Other qualifying complications such as hepatopulmonary syndrome

A MELD score around 15 has historically been associated with increasing survival benefit from transplantation, but clinical decompensation itself is an important indication for early evaluation.

13. Key Clinical Insight

Ascites + portal hypertension + impaired hepatic function + probable overt hepatic encephalopathy strongly indicate decompensated cirrhosis.

In this patient:

Long-term alcohol use + nodular liver + splenomegaly + ascites + jaundice + thrombocytopenia + low albumin + prolonged INR + confusion and asterixis = decompensated cirrhosis, most likely due to alcohol-associated liver disease, with portal hypertension and probable overt hepatic encephalopathy.

References

1.      Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884.

2.      Baveno VIII Faculty. Baveno VIII: Advancing Consensus in Portal Hypertension. Journal of Hepatology. 2026. doi:10.1016/j.jhep.2026.07.030.

3.      Nadim MK, Kellum JA, Forni LG, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative and International Club of Ascites joint multidisciplinary consensus meeting. Journal of Hepatology. 2024;81(1):163-183. doi:10.1016/j.jhep.2024.03.031.